



## NEW DRUG UPDATE

Sunday, December 2, 2018

1:00 – 4:15 P.M. (sign-in 12:30 P.M.)

Samford University Brock School of Business, Room 400

3 Contact hours of Pharmacy CE credit (0.3 CEUs) (Pharmacist & Pharmacy Technician credit)

### STATEMENT OF EDUCATIONAL NEED

Over the past two years, there has been a noticeable and significant increase in the number of FDA approvals for new molecular entities, combination drugs, and biologics. In 2016, the total of new drug approvals was 22, increasing to 46 in 2017 and 45 approvals to date in 2018. The approval of new medications provides promise and potential for innovation in terms of patient outcomes and the provision of care through the US healthcare system. Additionally, the approval of new medications provides opportunities to learn about unique or common safety information that will be essential for consideration when implementing a care plan and when communicating with patients and caregivers. The purpose of this knowledge-based activity is to update the pharmacist and pharmacy technician audience on the effectiveness and safety and handling of select new drug approvals for the inpatient and outpatient setting. Learning will be reinforced through activities and assessment.

#### Sources:

2017 saw the most new drugs approved in over 20 years. Fortune magazine website. <http://fortune.com/2018/01/02/new-drug-approvals/>. Accessed 10/15/18.

New drug approvals for 2018. US Food and Drug Administration website.

<https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm592464.htm>. Accessed 10/15/18.

New drug approvals for 2017. US Food and Drug Administration website.

<https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm>. Accessed 10/15/18.

New drug approvals for 2016. US Food and Drug Administration website.

<https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm483775.htm>. Accessed 10/15/18.

This is a knowledge-based CPE activity and appropriate for all pharmacists and pharmacy technicians. To receive credit, participants must attend the entire session and complete program assessments. Credit will be sent electronically through CPE Monitor within 30 days following the program. NABP e-Profile ID# and Date of Birth (mmdd) required.

#### \*Speakers:

Elizabeth W. Covington, Pharm.D.  
Assistant Professor of Pharmacy Practice  
Samford University McWhorter School of Pharmacy

Pilar Z. Murphy, Pharm.D., BCACP  
Associate professor of Pharmacy Practice  
Samford University McWhorter School of Pharmacy

\*Speakers have no relevant conflicts of interest to disclose.

#### Learning Objectives for pharmacists:

- Identify new drugs approved by the FDA in 2016-2018 for use in the inpatient setting (coagulation factor Xa [recombinant], angiotensin II, sodium zirconium cyclosilicate, meropenem/vaborbactam, delafloxacin, bezlotoxumab, plazomicin, eravacycline, omadacycline).
- Identify new drugs approved by the FDA in 2016-2018 for use in the outpatient setting (ereumab-aooe, semaglutide, dapagliflozin/saxagliptin, nebivolol/valsartan, ertugliflozin, plecantide, sumatriptan nasal powder, insulin glargine/lixisenatide, insulin degludec/liraglutide).
- Recall the FDA-approved indication, mechanism of action counseling points, and monitoring parameters for each of the drugs reviewed.

- Appraise the evidence supporting the approval and discuss potential role(s) in therapy for each of the drugs reviewed.

**Learning Objectives for pharmacy technicians:**

- Identify new drugs approved by the FDA in 2016-2018 for use in the inpatient setting (coagulation factor Xa [recombinant], angiotensin II, sodium zirconium cyclosilicate, meropenem/vaborbactam, delafloxacin, bezlotoxumab, plazomicin, eravacycline, omadacycline).
- Identify new drugs approved by the FDA in 2016-2018 for use in the outpatient setting (ereumab-aooe, semaglutide, dapagliflozin/saxagliptin, nebivolol/valsartan, ertugliflozin, plecantide, sumatriptan nasal powder, insulin glargine/lixisenatide, insulin degludec/liraglutide).
- Recall the FDA-approved indication, mechanism of action counseling points, and monitoring parameters for each of the drugs reviewed.
- Review storage information and dosage forms for each of the drugs reviewed.

**Agenda:**

12:30 P.M. Sign-In  
1:00 P.M. *Plug into New Drugs: New Options for the Inpatient Setting*  
2:00 P.M. Break  
2:15 P.M. *Plug into New Drugs: New Options for the Outpatient Setting*  
4:15 P.M. Dismissal

**Cost:**

Pharmacists - \$90  
Pharmacy technician - \$35

**Registration:** For online registration go to:

<http://www.samford.edu/pharmacy/continuing-education>

Preregistration closes at midnight November 29th. There will be no refunds unless cancellation is made before preregistration closes.

ACPE UAN 0002-0000-18-019-L01-P / 0002-0000-18-019-L01-T



Samford University McWhorter School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This ACPE-accredited CPE activity is conducted without commercial support or influence of any kind.